Mr. Ron Nagar reports

TEMPRAMED REPORTS RECORD JULY SALES AND STRONG AUGUST PERFORMANCE, WITH YEAR-TO-DATE SALES ALREADY EXCEEDING FULL-YEAR 2025 REVENUE

Tempramed Technologies Ltd. has provided an interim sales update regarding its recent commercial performance.

The company reports that July, 2026, sales reached approximately $522,000 (U.S.), representing the highest monthly sales level in Tempramed's history. August, 2026, sales reached approximately $403,000 (U.S.), representing the company's second-highest monthly sales result to date.

As a result of this performance, management expects Q3 2026 sales to be significantly stronger than Q3 2025, reflecting continued commercial momentum across Tempramed's growing portfolio of medication temperature-protection products and expanding distribution channels.

For the eight-month period ended Aug. 31, 2026, Tempramed recorded approximately $2.07-million (U.S.) in sales, already exceeding the company's total sales for the full 2025 fiscal year of approximately $1.8-million (U.S.).

"We are excited to share these sales results for the last few months as it shows significant growth and adoption in 2026 so far. As our financial statements for Q3 2026 are not expected until November, we believe it is important to provide the market with visibility into our recent sales performance. July was a record month for Tempramed, August was our second-highest month to date and our year-to-date sales have already surpassed total sales for all of last year," said Ron Nagar, chief executive officer of Tempramed.

"These results reflect growing market demand for our products and the early impact of our strategy to expand beyond direct-to-consumer sales into institutional, pharmacy, distributor and health care system channels," added Mr. Nagar. "While we remain focused on disciplined execution, the recent sales performance demonstrates that Tempramed is entering a new stage of commercial scale."

Tempramed believes its growth is supported by several key drivers, including increased awareness of medication temperature exposure, broader adoption of temperature-sensitive injectable therapies such as insulin and GLP-1 medications, expanding product availability through healthcare and pharmacy channels, and the company's continued transition toward a more diversified B2B (business-to-business) and institutional commercial model.

Management expects these trends to remain important drivers of Tempramed's long-term growth strategy as the company continues to expand access to its product portfolio across North America, Israel, Europe, Latin America, the Middle East and other target markets.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, anytime.

We seek Safe Harbor.